检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Efficacy And Safety Of Ruxolitinib In Elderly Patients (> 75 Years) With Myelofibrosis

Latagliata Roberto, Veroli Ambra Di, Alberto Palumbo Giuseppe,Bonifacio Massimiliano,Andriani Alessandro,Polverelli Nicola,Trawinska Malgorzata,Tiribelli Mario,Anaclerico Barbara,Benevolo Giulia,Petriccione Luca, M. Bruno,Centra Antonia,D'Adda Mariella,Crugnola Monica,Cavazzini Francesco,Bergamaschi Micaela,Tieghi Alessia,Ibatici Adalberto,Bosi Costanza,Perricone Margherita,Montanaro Marco,Cavo Michele,Breccia Massimo,Vianelli Nicola,Palandri Francesca

BLOOD（2016）

引用 1|浏览2
暂无评分
摘要
Background. Ruxolitinib (RUX) is the first commercially available JAK1/2 inhibitor that may control splenomegaly and systemic symptoms related to myelofibrosis (MF). Despite MF occur frequently in elderly patients (pts), no data are yet available on RUX efficacy and safety in this particularly frail population.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要